Displaying drugs 10251 - 10275 of 12494 in total
Daclizumab
Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences...
Investigational
Withdrawn
Matched Description: … of the Eu myeloma antibody. ... Regardless of the withdrawal of Zenapax, Biogen and Abbvie's Zinbryta (daclizumab), as indicated for ... the treatment of adult patients with relapsing forms of multiple sclerosis, was approved for use by the …
Etrolizumab
Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is typified by a chronic gastrointestinal inflammatory microenvironment, driven in part by the excessive infiltration and retention of intestinal-homing lymphocytes.[A244564, A244569, A244579, A244584] A recent class of drugs designed to impair lymphocyte homing, so-called "anti-trafficking agents" (ATAs), have shown some...
Investigational
Matched Description: … in undesirable blockade of lymphocyte CNS trafficking and reported cases of progressive multifocal leukoencephalopathy ... [A244574] In the case of [natalizumab], which targets the α4 integrin subunit, this has also resulted ... gastrointestinal inflammatory microenvironment, driven in part by the excessive infiltration and retention of …
Paliroden
Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous neurotrophines. Studies show that use of paliroden increased the rate of formation of both neural progenitors and mature neurons. It is indicated for use in Alzheimer's Disease and Parkinson’s.
Investigational
Matched Description: … Studies show that use of paliroden increased the rate of formation of both neural progenitors and mature ... Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous …
GB-13
GB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A.
Investigational
Matched Description: … mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A. ... GB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered …
CP-39,332
CP-39,332 is a serotonin-norepinephrine reuptake inhibitor (SNRI). It is part of a group of monoamine reuptake inhibitor stereoisomers including tametraline (1R,4S-), CP-24,442 (1S,4R-), CP-22,185 (cis-), and CP-22,186 that show varying efficiency. However, none of the members of this stereoisomers has been marketed.
Experimental
Matched Description: … However, none of the members of this stereoisomers has been marketed. ... It is part of a group of monoamine reuptake inhibitor stereoisomers including tametraline (1R,4S-), CP …
PI-103
PI-103 is an inhibitor of p110α of class I PI3K.
Investigational
Matched Description: … PI-103 is an inhibitor of p110α of class I PI3K.[A253092] …
Entolimod
Entolimod has been used in trials studying the treatment of Mucositis, Tongue Cancer, Colorectal Cancer, Stage IVA Verrucous Carcinoma of the Larynx, and Stage IVB Verrucous Carcinoma of the Larynx, among others.
Investigational
Matched Description: … , Stage IVA Verrucous Carcinoma of the Larynx, and Stage IVB Verrucous Carcinoma of the Larynx, among ... Entolimod has been used in trials studying the treatment of Mucositis, Tongue Cancer, Colorectal Cancer …
Efavaleukin alfa
Efavaleukin alfa is a fusion protein consisting of interleukin mutein fused to the C-terminus of an immunoglobulin G Fc domain by way of a G4S linker. It is under investigation in clinical trial NCT03422627 (Safety and Efficacy of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease).
Investigational
Matched Description: … G Fc domain by way of a G4S linker. ... Efavaleukin alfa is a fusion protein consisting of interleukin mutein fused to the C-terminus of an immunoglobulin ... It is under investigation in clinical trial NCT03422627 (Safety and Efficacy of AMG 592 in Subjects With …
NTx-265
NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause of death worldwide. In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of...
Investigational
Matched Description: … of death worldwide. ... NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and ... In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265. …
Tallimustine
Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the minor groove of DNA.[A182036,A182039] It's association with severe myelotoxicity lead to the end of its development in favour of α-halogenoacrylamide derivatives such as brostallicin, which have a favourable cytotoxicity/myelotoxicity ratio.[A182039,A182045] Newer generations of DNA...
Experimental
Matched Description: … minor groove of DNA. ... Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the ... [A182036,A182039] It's association with severe myelotoxicity lead to the end of its development in favour …
Stannsoporfin
Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing jaundice.
Investigational
Matched Description: … WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing ... Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of …
MUL001
MUL001 is live attenuated strain of Salmonella typhimurium being investigated for the treatment of schwannomas.
Investigational
Matched Description: … MUL001 is live attenuated strain of _Salmonella typhimurium_ being investigated for the treatment of …
Ramosetron
Ramosetron is a serotonin 5-HT3 receptor antagonist commonly employed to treat nausea and vomiting, in addition to certain diarrheal conditions. It is believed to have higher potency and longer antiemetic action than other 1st generation 5-HT3 antagonists such as ondansetron. Currently, ramosetron is only approved for use Japan and in...
Investigational
APR-548
APR-548 is an analog of eprenetapopt and a reactivator of mutant p53.
Investigational
Matched Description: … APR-548 is an analog of [eprenetapopt] and a reactivator of mutant p53. …
KB001
KB001 is a Humaneered™ PEGylated monoclonal antibody fragment for the treatment of life-threatening Pseudomonas aeruginosa infections, a common problem of cystic fibrosis and mechanically ventilated patients.
Investigational
Matched Description: … KB001 is a Humaneered™ PEGylated monoclonal antibody fragment for the treatment of life-threatening ... Pseudomonas aeruginosa infections, a common problem of cystic fibrosis and mechanically ventilated patients …
M0002
M0002 is an orally-active selective vasopressin antagonist that inhibits water re-absorption from the kidneys. It is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce profound diuresis without loss of electrolytes. It will be of major benefit to those patients not responding satisfactorily...
Investigational
Matched Description: … profound diuresis without loss of electrolytes. ... It will be of major benefit to those patients not responding satisfactorily to diuretics alone. ... It is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce …
Elezanumab
Elezanumab is under investigation in clinical trial NCT03737812 (A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis).
Investigational
Matched Description: … Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis). ... Elezanumab is under investigation in clinical trial NCT03737812 (A Study to Assess the Safety and Efficacy of …
MK-0773
MK-0773 is under investigation in clinical trial NCT00529659 (A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(mk-0773-005)).
Investigational
Matched Description: … MK-0773 is under investigation in clinical trial NCT00529659 (A Study of the Safety and Efficacy of MK ... -0773 in Women With Sarcopenia (Loss of Muscle Mass)(mk-0773-005)). …
5alpha-androstane-3beta,17alpha-diol
5alpha-androstane-3beta,17alpha-diol is the unspecified form of the steroid, normally a major metabolite of testosterone with androgenic activity. It has been implicated as a regulator of gonadotropin secretion.
Experimental
Matched Description: … of [testosterone] with androgenic activity. ... It has been implicated as a regulator of gonadotropin secretion. ... 5alpha-androstane-3beta,17alpha-diol is the unspecified form of the steroid, normally a major metabolite …
Demcizumab
Demcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung.
Investigational
Matched Description: … Demcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung. …
Chloropyramine
Chlorpyramine is a first generation antihistamine used in Eastern European countries to treat bronchial asthma as well as allergice rhinitis, allergic conjunctivitis, and other allergic reactions. It is also indicated for Quincke's edema, allergic reactions to insect bites, food and drug allergies, and anaphylactic shock.
Experimental
GSK-945237
GSK-945237 is under investigation in clinical trial NCT01039610 (A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237...
Investigational
Matched Description: … a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology ... Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.). ... Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of …
CTA018
CTA018 is a member of a new class of vitamin D analogues with a dual mechanism of action, called Vitamin D Signal Amplifiers. This proprietary new drug is both a potent inhibitor of CYP24 (the enzyme responsible for the breakdown of vitamin D) and a potent activator of vitamin D...
Investigational
Matched Description: … CTA018 is a member of a new class of vitamin D analogues with a dual mechanism of action, called Vitamin ... of vitamin D) and a potent activator of vitamin D signaling pathways. ... This proprietary new drug is both a potent inhibitor of CYP24 (the enzyme responsible for the breakdown …
Amediplase
Amediplase is a recombinant chimeric plasminogen activator, consisting of the kringle 2 domain from the A-chain of tissue plasminogen activator (t-PA) and the carboxy terminal region of pro-urokinase. [MeSH]
Investigational
Matched Description: … A-chain of tissue plasminogen activator (t-PA) and the carboxy terminal region of pro-urokinase. ... Amediplase is a recombinant chimeric plasminogen activator, consisting of the kringle 2 domain from the …
Molybdenum cofactor
Absence of molybdenum cofactor leads to accumulation of toxic levels of sulphite and neurological damage usually leading to death within months of birth, due to the lack of active sulfite oxidase.
Experimental
Matched Description: … Absence of molybdenum cofactor leads to accumulation of toxic levels of sulphite and neurological damage ... usually leading to death within months of birth, due to the lack of active sulfite oxidase. …
Displaying drugs 10251 - 10275 of 12494 in total